GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women (PK/GUD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00808405
Recruitment Status : Completed
First Posted : December 15, 2008
Results First Posted : May 18, 2012
Last Update Posted : December 11, 2013
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Connie Celum, University of Washington

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Triple (Participant, Care Provider, Investigator);   Primary Purpose: Treatment
Condition: Genital Herpes
Interventions: Drug: acyclovir
Drug: matching placebo

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Between January and December 2009, women from Johannesburg, South Africa and Lusaka, Zambia who had previously participated in the HPTN 039 (NCT00076232) study, as well as other women in the community who presented to the research clinics with genetic ulcer disease (GUD) during the recruitment period, were invited to participate in the study.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Acyclovir Acyclovir 400 mg orally three times daily
Placebo Matching placebo tablet

Participant Flow:   Overall Study
    Acyclovir   Placebo
STARTED   61   27 
COMPLETED   61   27 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Acyclovir Acyclovir 400 mg orally three times daily
Placebo Matching placebo tablet
Total Total of all reporting groups

Baseline Measures
   Acyclovir   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 61   27   88 
[Units: Participants]
<=18 years   0   0   0 
Between 18 and 65 years   61   27   88 
>=65 years   0   0   0 
[Units: Years]
Mean (Standard Deviation)
 38.66  (10.28)   38.15  (10.31)   38.5  (10.23) 
[Units: Participants]
Female   61   27   88 
Male   0   0   0 
Region of Enrollment 
[Units: Participants]
Zambia   31   13   44 
South Africa   30   14   44 

  Outcome Measures

1.  Primary:   Time to Healing of Genital Lesions   [ Time Frame: Days 1-5, 7, 9, 11, 13 ]

2.  Secondary:   Time to First Negative Herpes Simplex Virus (HSV) DNA PCR   [ Time Frame: Days 1-5, 7, 9, 11, 13 ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Connie Celum, MD, MPH
Organization: University of Washington
phone: 206-520-3824

Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: Connie Celum, University of Washington Identifier: NCT00808405     History of Changes
Other Study ID Numbers: 34708-A
U01AI052054 ( U.S. NIH Grant/Contract )
First Submitted: November 25, 2008
First Posted: December 15, 2008
Results First Submitted: April 20, 2012
Results First Posted: May 18, 2012
Last Update Posted: December 11, 2013